ArticleOncotarget2016

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

David G Cox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.